Medicare Cancer Treatment Coverage: Chemo, Radiation & More (2026)

Medicare covers cancer treatment: chemotherapy, radiation, surgery, oral cancer drugs, and clinical trials are all covered across Part A, Part B, and Part D. What you pay depends on where and how you're treated (Part A for an inpatient stay, Part B for outpatient chemo, radiation, and doctor visits, and Part D for oral drugs you take at home), and in 2026 a new $2,100 annual cap on out-of-pocket drug costs means patients no longer face unlimited bills for oral chemotherapy. This guide breaks down each part and what you'll actually owe.1

How Medicare splits cancer treatment coverage

Cancer treatment rarely fits into a single category. A patient might receive IV chemotherapy at an outpatient clinic on Tuesday, take an oral drug at home every day, and have a follow-up scan in the same week. Medicare covers all of these, but the billing runs through different parts depending on the setting and the treatment type.

The dividing line is largely where you receive care. Inpatient treatment (hospital admission) runs through Part A. Outpatient treatment, including most chemotherapy and radiation given at a clinic or doctor's office, runs through Part B. Oral drugs you take at home go through Part D.

Part A: inpatient chemotherapy and radiation

When cancer treatment requires a hospital admission, Part A pays. This includes chemotherapy administered during an inpatient stay, inpatient radiation, and any other cancer-related care delivered while you're admitted as a hospital inpatient.

Under Part A, you pay the inpatient hospital deductible of $1,736 per benefit period in 2026. Days 1 through 60 of a continuous inpatient stay carry no additional coinsurance after that deductible. From day 61 through day 90, a daily coinsurance of $434 applies.1,3

Most cancer chemotherapy is not delivered inpatient. The more common scenario is outpatient infusion, which runs through Part B instead.

Part B: outpatient chemotherapy and radiation

Part B covers chemotherapy you receive in a hospital outpatient department, your oncologist's office, or a freestanding infusion clinic. Per the CMS 2026 cost announcement, the cost structure is:1

• Annual Part B deductible: $283 (paid once per year, not per treatment)1
• Coinsurance: 20% of the Medicare-approved amount for each session1
• Outpatient copayment cap: for chemotherapy received in a hospital outpatient setting, your copayment will not exceed $1,736 in a benefit period, which is the same as the inpatient hospital deductible1

That cap is meaningful. A patient receiving frequent infusions could otherwise accumulate 20% coinsurance charges that add up significantly over the course of treatment. For hospital-outpatient chemotherapy, the cap limits how high the per-session copayment can go.1

Part B also covers radiation therapy received in an outpatient setting under the same cost structure: 20% after the $283 deductible.1

A worked example: what Medicare cancer treatment actually costs

Say you're on Original Medicare and your oncologist orders six outpatient infusion sessions at a hospital outpatient department. Assume, as an illustration, that the Medicare-approved amount is $2,000 per session (your real rate depends on the drug and the facility). Here is roughly how the math runs in 2026:1

• Session 1: You first meet the $283 annual Part B deductible. On a $2,000 session, that's $283 plus 20% of the remaining $1,717, or about $343 more, so roughly $626 for the first session.1
• Sessions 2 onward: The deductible is done. You pay 20% of the $2,000 Medicare-approved amount, or $400 per session.1
• The cap steps in. For chemotherapy in a hospital outpatient setting, your copayment for these services will not exceed $1,736 in the benefit period, even as the 20% coinsurance keeps adding up across sessions.1

The dollar figures above ($2,000 per session) are a hypothetical illustration, not a Medicare rate. What is fixed by the program is the $283 deductible, the 20% coinsurance, and the $1,736 hospital-outpatient copayment cap. Separately, if you also take a covered oral cancer drug under Part D, your out-of-pocket spending on those drugs stops at the $2,100 annual cap.1,2

Part D and oral cancer drugs: the $2,100 cap

Oral anticancer drugs are where the biggest change for Medicare beneficiaries happened in recent years. Under the Inflation Reduction Act's Part D redesign, the annual out-of-pocket cap on covered Part D drugs is $2,100 in 2026, per CMS. Once your out-of-pocket spending reaches that amount for the year, you pay $0 for covered Part D drugs for the rest of the calendar year.2,1

For cancer patients on expensive oral anticancer drugs, this is a substantial protection. Some targeted therapy drugs and oral chemotherapy agents carry list prices of several thousand dollars a month. Under the old Part D structure, patients could face crushing annual costs. Now, costs stop at $2,100.2

A worked example: what an expensive oral cancer drug actually costs you. Suppose you're prescribed an oral targeted therapy, like one of the tyrosine-kinase inhibitors used for chronic myeloid leukemia (CML), with a list price of several thousand dollars a month. On a 2026 Part D plan, what you pay for that drug counts toward the $2,100 annual out-of-pocket cap, and once your covered-drug spending reaches $2,100 for the year you pay $0 for covered drugs the rest of the year, no matter how high the list price is.2 Three things soften even that $2,100: if the cost lands early in the year, the Medicare Prescription Payment Plan lets you spread it into level monthly installments; if the same drug also comes in an infused form, your oncologist may be able to bill it under Part B instead; and if your income is limited, Extra Help lowers it further. So the realistic answer to "what will an expensive oral cancer drug cost me?" on Original Medicare with a Part D plan is no more than $2,100 for the year, and often far less.2,4

One important distinction: oral chemotherapy drugs that are also available in an equivalent injectable or infusible form may be covered under Part B rather than Part D, at the same 20% coinsurance that applies to IV chemo. If your oral drug has an IV equivalent and you're on Original Medicare, ask your prescribing oncologist whether the drug can be billed under Part B, and check with the infusion clinic or your pharmacist, since Part B coverage often results in lower out-of-pocket costs than Part D depending on the specific drug and plan.1

For oral drugs covered under Part D, the $2,100 annual cap applies. The Medicare Part D redesign guide goes into the full structure if you need it.2

Extra Help with Part D drug costs

Even a $2,100 cap can be hard to absorb for a cancer patient on a fixed income. If your income and resources are limited, you may qualify for Extra Help, also called the Part D Low-Income Subsidy (LIS), a federal program run by the Social Security Administration that sharply lowers what you pay for covered drugs.4

For 2026, full Extra Help is available to individuals with income below about $1,995 a month ($23,940 a year) and married couples with income below about $2,705 a month ($32,460 a year), within the program's resource limits. Enrollees who qualify pay no more than $5.10 for each covered generic drug and $12.65 for each covered brand-name drug in 2026, and $0 once out-of-pocket drug costs reach the $2,100 catastrophic threshold. You can apply through the Social Security Administration at ssa.gov/extrahelp or by calling 1-800-772-1213.4

Clinical trials

If you're participating in a qualifying clinical trial, Medicare covers the routine costs of care, per the Medicare clinical research studies guidelines. Routine costs are the standard-of-care services you'd receive even if you weren't in a trial: your doctor visits, lab tests, hospital care, and supportive treatments.1

What Medicare does not cover in a clinical trial: the experimental treatment itself, and any tests or drugs needed purely for research purposes (not for your medical care). The trial sponsor or the research institution typically covers those costs.1

The key qualifier is that the trial must be a "qualifying" clinical trial that meets federal criteria. Your oncologist or the research coordinator can confirm whether a specific trial qualifies.

What Medicare Advantage plans cover

If you're on a Medicare Advantage (MA) plan rather than Original Medicare, the plan covers all the same cancer treatments (chemotherapy, radiation, oral drugs) because MA plans must cover everything Original Medicare covers. The difference is in the cost-sharing details, prior authorization requirements, and network.

MA plans typically have their own copayment structures for chemotherapy and radiation rather than the standard 20% coinsurance. Some plans have lower per-visit costs; others have higher total out-of-pocket limits. The federally capped MA out-of-pocket maximum for in-network services in 2026 is $9,250, though many plans set lower caps.3

Prior authorization and your right to appeal

Prior authorization is more common in MA plans for cancer treatment, particularly for expensive drugs or newer therapies. This doesn't mean coverage will be denied, but it does mean your oncologist may need to go through an approval process before treatment starts. Ask the plan and your care team about this before treatment begins.

If your MA plan denies prior authorization or refuses to cover a treatment, you have the right to appeal. You can request a standard appeal, or, when waiting could seriously harm your health, an expedited (fast) appeal that the plan must generally decide within 72 hours. Your plan's denial notice explains how to file and the deadline. For free, one-on-one help understanding a denial and filing an appeal, contact your State Health Insurance Assistance Program (SHIP), a federally funded counseling service; you can find your local SHIP through Medicare or by calling 1-800-MEDICARE (1-800-633-4227).

Planning for Medicare cancer treatment costs

Between Part B coinsurance and Part D drug costs, cancer treatment on Medicare involves real out-of-pocket exposure. A few things help.

If you have Original Medicare, a Medigap (Medicare Supplement) policy covers the 20% Part B coinsurance on chemotherapy and radiation, which can eliminate most of your outpatient treatment costs. Medigap plans are standardized and federally regulated, so a given plan letter offers the same benefits no matter which carrier sells it. The guide to what Medicare doesn't cover has more on how Medigap works.5,1

If your income is limited, you may qualify for a Medicare Savings Program through your state's Medicaid agency, which can pay your Part B premium and in some cases your coinsurance; Medicare explains the four programs and how to apply. For help with drug costs specifically, apply for Extra Help through the Social Security Administration at ssa.gov/extrahelp. See the dual eligibility guide for how these fit together.

For Part D drug costs, the $2,100 annual cap applies to all beneficiaries regardless of income. If you reach it, you're done paying for covered drugs that year. If your drug costs are high early in the year, the Medicare Prescription Payment Plan (M3P), an official Medicare program every Part D and Medicare Advantage drug plan must offer, lets you spread your out-of-pocket payments across the calendar year in monthly installments rather than paying in full at the pharmacy. M3P doesn't lower your total drug costs; it changes when you pay them.2

Learn More

Find personalized help understanding your Medicare cancer coverage at brevy.com.

The information on Brevy.com is for educational purposes only and is not a substitute for professional legal, financial, or medical advice. Rules vary by state and program and change frequently. Always verify with the relevant agency or a qualified professional. Brevy is not a law firm, financial advisor, or healthcare provider.